trending Market Intelligence /marketintelligence/en/news-insights/trending/XZWxqWaE4e_s7eGcqpS-lA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Becton Dickinson gets US FDA approval for 1st stent to unblock certain veins

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Becton Dickinson gets US FDA approval for 1st stent to unblock certain veins

Becton Dickinson and Co. said the U.S. Food and Drug Administration approved the first-of-its-kind Venovo stent to restore blood flow in certain veins near the groin.

Venovo received regulatory approval to treat iliofemoral venous occlusive disease, which results from impaired blood flow in the iliofemoral vein due to certain diseases.

These diseases include acute or chronic deep-vein thrombosis, post-thrombotic syndrome, iliofemoral vein compression including May-Thurner Syndrome or a combination of all of these.

Chronic deep-vein thrombosis is characterized by a blood clot that scars the vein and does not allow blood to flow through effectively, and May-Thurner syndrome is caused when one of the veins in the pelvis is compressed by an artery, leading to a clot developing.

The Franklin Lakes, N.J.-based medical-device maker said the approval is based on data from the Vernacular trial, which involved 170 patients and demonstrated the safety and effectiveness of Venovo.